Outcomes of High-Dose Intracoronary Adenosine Protocol in Saphenous Venous Graft Percutaneous Coronary Intervention: A 15-Year Single-Center Experience

Journal of the Society for Cardiovascular Angiography & Interventions 2026 Open access

Read full text
Authors: Naeem Khan Tahirkheli, Mishal Zehra, Sufyan Shahid, Zaigham ul Islam, Muzaffar Ali Zahidi, Minahil Iqbal, Ahsan Ahmad, Muhammad Shuaib Abid, Humza Saeed, Iftikhar Ch, Ahmed Arham Niaz, Mishal Afzal
+3 more Poonam Bai, Wajahat Alam Lodhi, Salman Khalid
DOI: 10.1016/j.jscai.2025.104162
Cited by: 0
References: 20

Abstract

Background Saphenous vein graft (SVG) percutaneous coronary intervention (PCI) carries a high-risk of slow or no-reflow (SNR)—up to 15% in stable ischemia and 29% in acute coronary syndrome (ACS)—leading to higher major adverse cardiovascular event rates. Evidence on high-dose intracoronary adenosine for SNR prevention remains limited. Methods We analyzed 171 patients with stable ischemic heart disease or ACS who underwent SVG PCI without embolic protection devices from 2010 to 2024 at our center. All received 200 to 400 μg intracoronary adenosine within 30 seconds just prior to each balloon or stent inflation, and post-PCI outcomes were evaluated. Results Of 171 patients, 71.2% were mene, and 83% presented with ACS. Pre-PCI Thrombolysis in Myocardial Infarction (TIMI) flow was

Fields of Study & Subjects

Coronary Interventions and Diagnostics Antiplatelet Therapy and Cardiovascular Diseases Acute Myocardial Infarction Research

Publication details

Journal / source
Journal of the Society for Cardiovascular Angiography & Interventions
Volume
5
Issue
2
Pages
104162–104162
Publication date
13 January 2026
Language
EN